

Top Ten Deficiencies for Liquid Drug Products

Allison A. Aldridge, Ph.D.*
Perpetue Bataille Backer, Ph.D.,
Christopher Mayer-Bacon, Ph.D., Sateesh Sathigari, Ph.D.

Consumer Safety Officer
OPMA/OPQ
CDER | US FDA

Generic Drugs Forum (GDF)– April 22-23 January 16, 2020

Disclaimer

This presentation reflects the views of the speaker and should not be construed to represent FDA's views or policies

Everyone deserves
confidence in their *next* dose
of medicine.


Pharmaceutical quality
assures the
availability,
safety,
and efficacy
of *every* dose.

Office of Pharmaceutical Manufacturing Assessment



- Mission: Quality pharmaceuticals are consistently manufactured over product lifecycle
- Vision: To be the premier global regulatory organization for holistic assessment

Office of Pharmaceutical Manufacturing Assessment, cont'd



**One Quality Voice
through
Integrated
Quality
Assessment
teams**

A network diagram with six green circular nodes connected by light blue lines. In the center of the network are three stylized human figures in blue and purple, representing a team or integrated quality assessment.

Learning Objectives



- FDA efforts to expedite drug approvals
- Analyze common manufacturing deficiency trends
- Review top ten deficiencies
- Identify documents to help applicants with submissions

FDA Enhancements



- Sending information requests (IRs) and discipline letters (DRLs) late in the assessment cycle (GDUFA III)
- Four Part Harmony (PDUFA VII) for IRs

Four Part Harmony

- Acknowledge information provided
- Identify the issue
- Identify information required to make a regulatory decision
- Provide specific reference or information to support request

Liquid Drug Products



- Injectables
- Oral dosage forms
- Topicals
- Insufflates



Poll Question




Which unit operation do you think has the number one deficiency?

- A. Mixing
- B. Filtration
- C. Filling/Sealing
- D. Packaging

Methods


- Number of IQAs and IRs (Deficiencies)



Methods, cont'd

- IRs categorized via keyword searches using VBA Script
- Categories included unit operations and other IQA sections
- Keyword examples included filling, packaging, and in-process controls (IPCs)

Deficiencies by Keyword Search



Results



Unit Operations


- Mixing (compounding)
- Filtration
- Filling/sealing
- Lyophilization
- Packaging

Other IQA Sections


- Drug substance attributes




Mixing (Compounding)





Filtration




Filling/Sealing




Lyophilization




Packaging



Other



Drug Substance Attributes



Top Ten Deficiencies



10. Drug Substance Attributes-Solubility (n=55)



9. Drug Substance Attributes-pH (n=61)



8. Mixing-Process Parameters (n=62)



7. Filling/Sealing-E&L (n=64)

Top Ten Deficiencies, cont'd



6. Filling/Sealing-Sampling Plan (n=76)



5. Mixing-IPCs (n=125)



4. Filling/Sealing-Flush Volume (n=159)



3. Mixing-Batch Record (n=167)

Top Ten Deficiencies, cont'd



2. Filling/Sealing-IPCs
(n=375)



1. Filling/Sealing
Batch Record (n=376)

Reference Documents



- FDA Guidances
- 21 CFR 210 and 211
- United States Pharmacopeia (USP)

Take Home Message

- The goal is quicker approvals
- The filling unit operation had the most deficiencies
- Refer to FDA guidances, 21 CFR 210 and 211 and the USP

Acknowledgements



- David McChesney
- Alexander Doura
- James Norman
- Vidya Pai
- Ying Zhang



Challenge Question #1



What is one of the FDA enhancements to help with quicker approvals:

- A. Complete response letters
- B. Refusing to file applications
- C. Sending IRS and DRLs late in the assessment cycle
- D. Four Part Harmony for IRs

Challenge Question #2



Which of the following statements is **NOT** true?

- A. The most common mixing operation deficiency was batch records.
- B. The filling/sealing operation had the least number of deficiencies.
- C. The most common drug substance attribute deficiency was pH.
- D. Filtration deficiencies did not make the top ten.

Questions?

Allison A. Aldridge, Ph.D.

Consumer Safety Officer

OPMA/OPQ

CDER | US FDA

www.fda.gov